IVF Services Market 2025

IVF services Market Size

The global IVF services market reached a value of nearly $19,577.23 million in 2024, having grown at a compound annual growth rate (CAGR) of 7.89% since 2019. The market is expected to grow from $19,577.23 million in 2024 to $33,675.49 million in 2029 at a rate of 11.46%. The market is then expected to grow at a CAGR of 10.74% from 2029 and reach $56,094.87 million in 2034. Growth in the historic period resulted from rising infertility rates, delayed parenthood, growth of fertility clinics, government initiatives and increasing incidence of lifestyle disorders. Factors that negatively affected growth in the historic period were the high cost of IVF treatment and limited insurance coverage. Going forward, increasing awareness and acceptance of IVF, favorable regulatory reforms in developed markets, rising maternal age and expansion of IVF service providers in emerging markets will drive growth. Factor that could hinder the growth of the IVF services market in the future include legal and ethical concerns and lack of skilled professionals.

IVF services Market Drivers

The key drivers of the IVF services market include: Rising Infertility Rates The rising infertility rates supported the growth of the IVF services market during the historic period. Infertility affects both men and women and the rising incidence across genders has significantly expanded the addressable market for IVF services. Factors such as lifestyle shifts, heightened stress levels, delayed parenthood and underlying health conditions have accelerated the demand for assisted reproductive technologies. This growing demand has attracted significant investment in the fertility tech sector. As a result, more IVF clinics are opening, advanced technologies like embryo freezing and genetic testing are being adopted, and services are becoming more accessible in both urban and semi-urban areas. For instance, in April 2023, according to the World Health Organization (WHO), a Switzerland-based specialized agency of the United Nations responsible for international public health, reported that around 17.5% of the adult population roughly 1 in 6 worldwide experience infertility, showing the urgent need to increase access to affordable, high-quality fertility care for those in need. Therefore, the rising infertility rates drove the growth of the IVF services market.

IVF services Market Restraints

The key restraints on the IVF services market include: High Cost Of IVF Treatment The high cost of IVF treatment restricted the growth of the IVF services market, during the historic period. IVF treatments are expensive, along with additional costs for medications, consultations and diagnostics. Many individuals cannot afford these out-of-pocket expenses, especially in regions without insurance coverage. This financial barrier limits access to IVF, reduces adoption rates and slows market growth. Moreover, since many patients require multiple cycles for success, the cumulative cost further deters continued treatment. For instance, in February 2024, according to GoodRx, a US-based company that provides consumers with the ability to compare prescription drug prices at various pharmacies, on average, a single cycle of in vitro fertilization (IVF)—which includes clinic procedures, bloodwork, fertility medications and genetic testing for embryos—can cost between $15,000 and $30,000. Therefore, the high cost of IVF treatment restrained the growth of the IVF services market.

IVF services Market Trends

Major trends shaping the IVF services market include: Expanding Fertility Access Through Strategic Partnerships In Regional Markets Major companies operating in the in vitro fertilization (IVF) services market are focusing on strategic partnerships to expand their geographic reach, enhance service offerings and integrate advanced technologies. These collaborations enable providers to deliver more personalized and efficient fertility care while tapping into underserved regional markets. For example, in August 2024, Jindal IVF, an India-based fertility clinic, partnered with Mandav Hospital, an India-based hospital to expand its fertility services to Mandi, Himachal Pradesh. This collaboration aims to provide advanced reproductive healthcare to the local community, leveraging Jindal IVF's expertise in assisted reproductive technologies. By establishing a presence in Mandi, Jindal IVF continues its mission to make fertility treatments more accessible across Northern India. Moreover, in March 2024, Alife Health, a US-based fertility technology company, partnered with Boston IVF, a US-based fertility center, to pilot the country's first AI tool for IVF medication optimization. Boston IVF will implement Alife's Stim Assist software, which is designed to help IVF clinicians retrieve the optimal number of eggs for each patient and reduce overall medication costs. This collaboration aims to enhance IVF treatment protocols and improve success rates. Additionally, For example, in July 2023, Ivy Fertility Network, a US-based network of fertility clinics, expanded its partnership with TMRW Life Sciences, a US-based biotechnology company specializing in the automation and digitization of in vitro fertilization (IVF) laboratories, to implement TMRW's automated platform for specimen management across all 13 of its clinics in the United States. This technology reduces potential points of failure by 94% compared to manual systems, providing enhanced security and peace of mind to patients. Advancing Embryo Selection with Whole Genome Sequencing in IVF Services Major companies operating in the in vitro fertilization (IVF) services market are focusing on developing whole genome sequencing tests to enhance embryo selection and improve the success rates of IVF procedures. These advancements aim to minimize the risk of genetic disorders, ensuring better long-term health outcomes for both the child and the parents. For example, in January 2024, Orchid Health, a US-based clinic, offering personalized care in fertility and sexual health, launched whole genome sequencing (WGS) test for preimplantation embryos. This test sequences over 99% of an embryo's genome, a significant advancement compared to traditional preimplantation genetic testing (PGT) methods that analyze less than 1% of the genome. By providing a comprehensive genetic profile, the test enables prospective parents undergoing vitro fertilization (IVF) to identify potential risks for a wide range of genetic conditions, including neurodevelopmental disorders, congenital anomalies and various cancers, before embryo implantation.

Opportunities And Recommendations In The IVF services Market

Opportunities – The top opportunities in the IVF services market segmented by cycle type will arise in the fresh IVF cycles(non-donor) segment, which will gain $6,569.65 million of global annual sales by 2029. The top opportunities in the IVF services market segmented by service provider will arise in the fertility clinics segment, which will gain $11,268.68 million of global annual sales by 2029. The IVF services market size will gain the most in the USA at $4,068.39 million. Recommendations- To take advantage of the opportunities, the business research company recommends the IVF services companies to focus on innovation and regional expansion, focus on advancing genetic testing in IVF procedures, focus on expanding fresh IVF cycles and leveraging technological advancements, expand in emerging markets, focus on strategic partnerships and technology integration, focus on competitive and tiered pricing to maximize market reach and profitability, focus on digital channels and international patient acquisition, focus on physician referrals and professional networks and focus on expanding fertility clinic services to maximize growth.